6-Methylflavone

6-Methylflavone

SCHEMBL4648879

Cc1ccc2oc(-c3ccccc3)cc(=O)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 1.00
CYP3A4 P08684 3/20 1.00
MAPT P10636 3/20 1.00
HPGD P15428 3/20 1.00
KDM4E B2RXH2 2/20 1.00
ALDH1A1 P00352 2/20 1.00
HSD17B10 Q99714 2/20 1.00
MAPK1 P28482 1/20 0.80
TDP1 Q9NUW8 1/20 0.80
PLA2G2A P14555 1/20 0.73
PLA2G4A P47712 1/20 0.73
CSNK2A2 P19784 1/20 0.73
CSNK2B P67870 1/20 0.73
CSNK2A1 P68400 1/20 0.73
TNKS O95271 4/20 0.69
PARP1 P09874 2/20 0.69
TNKS2 Q9H2K2 2/20 0.69
MAOB P27338 1/20 0.69
PARP2 Q9UGN5 1/20 0.69
KCNA5 P22460 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
6-Methylflavone SCHEMBL29804485 1.00 TP53 (1.00) TP53CYP3A4MAPTHPGDKDM4E
SCHEMBL10024074 0.90 CSNK2A2 (0.82) TP53CYP3A4MAPTHPGDKDM4E
7-Methylflavone SCHEMBL9137885 0.87 TP53 (0.77) TP53CYP3A4MAPTHPGDKDM4E
SCHEMBL5433487 0.84 CSNK2A2 (1.00) TP53CYP3A4MAPTHPGDKDM4E
SCHEMBL4650552 0.84 CSNK2A2 (0.74) TP53CYP3A4MAPTHPGDKDM4E
Flavone SCHEMBL27560931 0.84 TNKS (0.85) TP53CYP3A4MAPTHPGDKDM4E
SCHEMBL5424662 0.84 CYP3A4 (0.79) TP53CYP3A4MAPTHPGDKDM4E
SCHEMBL28043561 0.84 CSNK2A2 (0.72) TP53CYP3A4MAPTHPGDKDM4E
SCHEMBL24227286 0.83 PLA2G2A (0.97) TP53CYP3A4MAPTHPGDKDM4E
SCHEMBL28100458 0.82 PLA2G2A (0.76) TP53CYP3A4MAPTHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113512018-B Flavonoid compound and preparation method and application thereof 合肥工业大学 2023-07-18 CN claimed
US-11596657-B2 Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) 2023-03-07 US claimed
US-20220331431-A1 COMPOSITIONS AND METHODS OF SUPPRESSING AVERSIVENESS OF PHARMACEUTICALS AND INGESTIBLE MATERIALS MONELL CHEMICAL SENSES CENTRE (US) 2022-10-20 US claimed
CN-109096455-B Preparation method of modified alkyl phenolic tackifying resin and rubber composition thereof 山东圣泉新材料股份有限公司 2021-07-06 CN claimed
WO-2021050449-A1 COMPOSITIONS AND METHODS OF SUPPRESSING AVERSIVENESS OF PHARMACEUTICALS AND INGESTIBLE MATERIALS MONELL CHEMICAL SENSES CENTER (US) 2021-03-18 WO claimed
US-20190282638-A1 USE OF AHR AGONIST FOR THE PREVENTIVE OR CURATIVE TREATMENT OF METABOLIC SYNDROME AND THE ASSOCIATED DISORDERS INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) 2019-09-19 US claimed
EP-3522902-A1 USE OF AHR AGONIST FOR THE PREVENTIVE OR CURATIVE TREATMENT OF METABOLIC SYNDROME AND THE ASSOCIATED DISORDERS Institut National de la Recherche Agronomique (FR) 2019-08-14 EP claimed
WO-2018065132-A1 USE OF AHR AGONIST FOR THE PREVENTIVE OR CURATIVE TREATMENT OF METABOLIC SYNDROME AND THE ASSOCIATED DISORDERS. INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) 2018-04-12 WO claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
EP-3522902-B1 PROBIOTIC BACTERIA PRODUCING AN AHR AGONIST AND THEIR USE IN THE TREATMENT OF METABOLIC SYNDROME AND OBESITY INSTITUT NATIONAL DE RECH POUR LAGRICULTURE LALIMENTATION ET LENVIRONNEMENT (FR) 2025-09-03 EP disclosed
US-20250263774-A1 DISCOVERING NEW XENOBIOTIC SUBSTRATES OF AN UDP-GLYCOSYLTRANSFERASE WITH A HIGH-THROUGHPUT METHOD UNIV NORTH TEXAS (US) 2025-08-21 US disclosed
US-12368049-B2 Protective film agent and processing method of workpiece DISCO CORPORATION (JP) 2025-07-22 US disclosed
CN-118638850-A Application of GmSTOP1-3 gene in regulating anabolism of soybean root flavonoid substances and reducing accumulation of plant ROS 华南农业大学 2024-09-13 CN disclosed
US-20030125264-A1 Methods For Treating Wounds KIMBERLY-CLARK WORLDWIDE, INC. 2003-07-03 US disclosed
US-6555523-B1 Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus CASCADE ESTATES LTD. (MU) 2003-04-29 US disclosed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220331431-A1 COMPOSITIONS AND METHODS OF SUPPRESSING AVERSIVENESS OF PHARMACEUTICALS AND INGESTIBLE MATERIALS HTR6, FOS, API5 TP53 3455/4885CYP3A4 1429/4885MAPT 3255/4885
US-20030125264-A1 Methods For Treating Wounds FGF2, MMP1, FIBP TP53 841/4885CYP3A4 3010/4885MAPT 4313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.